These results suggested that the drug combination effect on lung cancer cell viability was unlikely to be the result of changes in cellular energy metabolism, which prompted us to test whether IDH2-mediated changes in mitochondrial ROS generation could be a contributing mechanism. The gene discussed is IDH2; the disease is lung carcinoma.